drug
AMBRISENTAN
Marketedupdated 3mo agoby Sigmapharm Laboratories LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(17)
approval · 17
Mar 28, 2019
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Apr 10, 2019
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Nov 29, 2019
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Dec 22, 2020
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Dec 22, 2020
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Jun 8, 2021
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Jun 8, 2021
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
May 19, 2022
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Aug 19, 2024
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Aug 19, 2024
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Aug 19, 2024
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Apr 4, 2025
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Apr 4, 2025
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Apr 4, 2025
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Sep 19, 2025
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Feb 17, 2026
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Feb 17, 2026
approval
AMBRISENTAN — FDA approval
AMBRISENTAN
→
Trials studying AMBRISENTAN
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 11, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Oct 14, 2031method-of-use (U-1965)US 9549926
- Oct 14, 2031method-of-use (U-1965)US 9549926
- Dec 11, 2027method-of-use (U-1754)US 83779331.3y
- Dec 11, 2027method-of-use (U-1754)US 83779331.3y
- Dec 11, 2027method-of-use (U-1754)US 94747521.3y
- Dec 11, 2027method-of-use (U-1754)US 94747521.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that